Geparin-Indar solution for injections 5000 IU/ml. 5 ml. (25000 IU) vial №5


Manufacturer: Germany

Treatment of diseases of the superficial veins, such as varicose veins, and related complications, phlebothrombosis, thrombophlebitis, and superficial periflebitis. Postoperative varicose phlebitis, complications after surgical removal of the saphenous vein of the leg. Injuries and bruises, infiltrates and localized edema, subcutaneous hematomas. Injuries and sprains of muscle-tendon and capsule-connected structures.



Geparin-Indar Composition
active substance: sodium heparin;

1 ml of injection solution contains 5000 IU of sodium heparin;

excipients: benzyl alcohol, sodium chloride, water for injection.

Geparin-Indar Dosage form

Basic physical and chemical properties: transparent, colorless or light yellow liquid.

Geparin-Indar Pharmacotherapeutic group
Antithrombotic agents. Heparin group. ATX code B01A B01.

Heparin is a glycosaminoglycan (mucopolysaccharides) that consists of sulfated D-glucosamine and D-glucuronic acid residues.

Heparin is a direct-acting anticoagulant. In solution, heparin has a negative charge, which contributes to its interaction with proteins that are involved in the process of blood clotting. Heparin binds to antithrombin III (heparin cofactor) and inhibits the process of blood coagulation by inactivating factors V, VII, IX, X. This neutralizes factors that activate blood coagulation (kallikrein, IXa, Xa, XIa, XIIa), the transition of prothrombin to thrombin. When the thrombus formation process has already begun, large amounts of heparin can inhibit further coagulation by inactivating thrombin and inhibiting the conversion of fibrinogen to fibrin. Heparin also prevents the formation of stable fibrin clots by inhibiting the activation of the fibrin-stabilizing factor. When administered parenterally, heparin slows down blood clotting, activates the process of fibrinolysis, inhibits the activity of certain enzymes (hyaluronidase, phosphatase, trypsin), slowing down the action of prostacyclin on platelet aggregation caused by the action of adenosine diphosphate.

After intravenous infusion, the maximum level in blood plasma is reached in a few minutes, after a slow infusion – no later than 2-3 minutes, after drug administration – after 40-60 minutes. The volume of distribution of heparin corresponds to the volume of blood plasma and increases significantly with an increase in the dose of the drug. Plasma proteins at a heparin concentration of 2 IU / ml of blood bind up to 95% of the drug, at higher concentrations – less. Heparin is partially metabolized in the liver. Close
20% is found in urine in the form of unchanged heparin and uroheparin (50% of the active substance is active). The biological half-life is 1.32-1.72 hours. The plasma half-life is 30-60 minutes. In liver failure, heparin accumulates. Heparin does not penetrate into breast milk, poorly penetrates the placenta.

Prevention and treatment of thromboembolic diseases and their complications (acute coronary syndrome, thrombosis and embolism of the great veins and arteries, cerebral vessels, eyes, phase I of disseminated intravascular coagulation syndrome, permanent form of atrial fibrillation with embolization)
prevention of postoperative venous thrombosis and pulmonary embolism (in a low-dose regimen) in patients who have undergone surgery, or in those who, for any other reason, have a risk of developing thromboembolic disease;
prevention of blood clotting in laboratory tests, dialysis, extracorporeal circulation, heart and vascular surgery, direct blood transfusion.

Hypersensitivity to heparin and / or benzyl alcohol, hemophilia, hemorrhagic diathesis, suspected heparin immune thrombocytopenia, stomach and duodenal ulcer, severe arterial hypertension, cirrhosis of the liver, accompanied by varicose veins of the esophagus, severe renal and hepatic insufficiency , recent surgical interventions, especially neurosurgical and ophthalmic, ulcerative colitis, malignant neoplasms, hemorrhagic stroke (first 2-3 days), traumatic brain injury, retinopathy, hemorrhage in the eye tissue, destructive pulmonary tuberculosis; encephalomalacia; hemorrhagic pancreatic necrosis; bleeding of any localization (open stomach ulcer, intracranial bleeding), with the exception of hemorrhage caused by embolic pulmonary infarction (hemoptysis) or kidney (hematuria) history of repeated bleeding, regardless of localization; increased vascular permeability (for example, with Werlhof’s disease), a state of shock; threatening abortion.